3 not yet recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 3 |
| Phase 1 | 2 | Not yet recruiting 2 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia Daratumumab - Aplastic Anemia, Refractory | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 37 | 2025-12-10 | 2025-12-17 |
| Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. Azacitidine (AZA) - Acute Myeloid Leukemia (AML), Relapse | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 51 | 2025-01-16 | 2025-01-17 |
| Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion T-reg depleted DLI - Hematological Malignancies, Regulatory T Cell Depletion | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 27 | 2024-03-01 | 2024-02-14 |
Recurrence (3) · Anemia, Aplastic (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1)
Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Neoplasms (2) · Anemia (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1)
Azacitidine (1) · daratumumab (1)
Assistance Publique - Hôpitaux de Paris (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)
China (1)